Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Bonus Story Members of Congress Bought These 5 Stocks—Should You?By Chris Markoch. Article Posted: 3/18/2026. 
Key Points - Congressional disclosures highlighted five stocks recently traded by lawmakers, including BigBear.ai, Eli Lilly, and Broadcom.
- AI, defense, semiconductors, and GLP-1 healthcare trends appear across several trades, pointing to sectors with strong growth narratives.
- While disclosures lag by up to 45 days, tracking congressional trades can provide useful watchlist ideas for individual investors.
- Special Report: Elon's "Hidden" Company
Lawmakers on both sides of the aisle have recently proposed banning members of Congress from trading individual stocks while in office. The issue goes back to the STOCK Act of 2012, which was intended to improve transparency by requiring politicians to disclose trades within 45 days. Critics say that falls short. More recent bills, including the ETHICS Act and the TRUST in Congress Act, would take a tougher stance by prohibiting active stock trading by members altogether. SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation could reach over $1.5 trillion. But since SpaceX isn't publicly traded, most investors assume they have no way to invest—that assumption may be wrong. According to veteran investor Matt McCall, there's a little-known public investment vehicle that provides exposure to SpaceX and dozens of other private companies, and today shares trade for less than $30. Click here to see the full story Because legislation can take a long time to pass, the 45-day disclosure window remains one of the few tools everyday investors have to see where elected officials are putting their own money. A review of the most recent 90 days of filings turned up five stocks worth watching, from a small-cap AI defense play to a large-cap semiconductor leader at the center of the AI infrastructure boom. BigBear.ai: A Small-Cap AI Defense Play Getting Repeat Attention Representative Lisa McClain of Michigan made two separate purchases of BigBear.ai (NYSE: BBAI) in February, first on the 4th and again on the 6th. Combined, the purchases were valued between $16,000 and $65,000. BigBear.ai is a small-cap decision intelligence company that derives a significant portion of its revenue from U.S. government contracts in defense and national security. McClain is not a first-time buyer. In August 2024, she reportedly became the first politician to disclose owning BBAI stock, and her repeat purchases suggest this is more than a one-off. Her seat on the Financial Services Subcommittee on National Security is context worth keeping in mind. Cracker Barrel: A Quick Trade From a Top Congressional Performer Representative Tim Moore of North Carolina was named the top-performing member of Congress for stock trades in 2025, with a reported 52% gain. He was active in Cracker Barrel (NASDAQ: CBRL) around the new year. Moore purchased CBRL on Dec. 31, then sold a larger position days later on Jan. 5, appearing to book a quick profit on a beaten-down restaurant stock. The buy was in the $15,000–$50,000 range; the sale was $50,000–$100,000. The trade reads more like a tactical, short-term move than a conviction hold, but when someone who outperformed the S&P 500 by a wide margin makes a move, even a brief one, it attracts attention. Simply Good Foods: A Double Buy on a Beaten-Down Nutrition Stock Simply Good Foods (NASDAQ: SMPL) is another intriguing purchase by Representative Moore. He made two buys in February, on the 3rd and again on the 11th, each valued between $15,000 and $50,000. According to Quiver Quantitative data, Moore is reportedly the first member of Congress to buy SMPL in recent years. Simply Good Foods, the maker of Atkins and Quest nutrition products, has seen its stock fall roughly 53% over the past year. Moore's double purchase suggests he is buying into weakness in a new position. There is also a macro tailwind argument: as GLP-1 weight-loss drugs shift consumer behavior toward high-protein, low-carb diets, consumer staples like Simply Good Foods could benefit. Eli Lilly: GLP-1 Momentum and an Upcoming Obesity Drug Catalyst Representative David Taylor of Ohio purchased Eli Lilly (NYSE: LLY) on Feb. 26; the trade was disclosed on March 6. The purchase coincided with Lilly's CFO publicly confirming the company was on track to launch its oral obesity drug, orforglipron, in the second quarter of 2025, pending FDA approval. To be fair, orforglipron has been in public conversation for months, and the disclosure timeline is standard under the STOCK Act. Still, the sequence of events is the kind of detail that draws attention. The fundamental case for LLY is strong: it holds roughly 60% of the U.S. GLP-1 market and has about $1.5 billion in pre-launch inventory ready to ship within a week of FDA approval. Additionally, Medicare coverage of the oral pill could begin as early as April at an estimated $50 per month for eligible patients. Broadcom: Multiple Congressional Buys in a Leading AI Chip Stock Broadcom (NASDAQ: AVGO) stands out because the buying wasn't limited to a single member—three separate members of Congress purchased AVGO shares in the past 90 days. Representative Gilbert Ray Cisneros Jr. made purchases in October, November and December. Senator Shelley Moore Capito bought in early February. And Representative David Taylor picked up Broadcom shares on Jan. 29. Broadcom reported AI revenue of $12 billion for fiscal 2025, a 74% year-over-year increase, and guided for $10.7 billion in AI revenue in Q1 2026 alone. The company is also a significant federal contractor, which may give congressional members additional context beyond Wall Street research when assessing its prospects. Congressional Trades Are a Clue, Not a Trading Signal Investors should remember that congressional trade disclosures are a data point, not a buy or sell signal. By the time a disclosure is public, the trade is often already 45 days old and the market may have priced in the thesis. Correlation between a member's role and a stock purchase does not imply impropriety. That said, watching where informed, well-connected individuals put their own money—especially when multiple members converge on the same name—can be a useful part of due diligence. These five stocks may be worth adding to a watchlist, but complete your own independent research before taking any action. | 
No comments:
Post a Comment